Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
about
Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.Low-frequency repetitive transcranial magnetic stimulation on Parkinson motor function: a meta-analysis of randomised controlled trials.The safety of istradefylline for the treatment of Parkinson's disease.New and emerging medical therapies in Parkinson's disease.Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy.Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.
P2860
Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Adenosine A2A receptor antagon ...... on's disease: a meta-analysis.
@ast
Adenosine A2A receptor antagon ...... on's disease: a meta-analysis.
@en
Adenosine A2A receptor antagon ...... on's disease: a meta-analysis.
@nl
type
label
Adenosine A2A receptor antagon ...... on's disease: a meta-analysis.
@ast
Adenosine A2A receptor antagon ...... on's disease: a meta-analysis.
@en
Adenosine A2A receptor antagon ...... on's disease: a meta-analysis.
@nl
prefLabel
Adenosine A2A receptor antagon ...... on's disease: a meta-analysis.
@ast
Adenosine A2A receptor antagon ...... on's disease: a meta-analysis.
@en
Adenosine A2A receptor antagon ...... on's disease: a meta-analysis.
@nl
P2093
P2860
P1476
Adenosine A2A receptor antagon ...... on's disease: a meta-analysis.
@en
P2093
Chaoli Wang
Guowei Wang
Jinqing Li
Yajie Wang
P2860
P304
P356
10.1179/1743132814Y.0000000375
P577
2014-04-13T00:00:00Z